This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00587431
First received: December 21, 2007
Last updated: August 5, 2014
Last verified: August 2014
Results First Received: January 21, 2014  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Prostate Cancer
Interventions: Drug: GnRh (Leuprolide)
Drug: Testosterone Gel
Drug: Docetaxel

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Protocol Open to Accrual: 07/08/2003

Protocol Closed to Accrual: 02/28/2006

Primary Completion Date: 02/26/2008

Recruitment Location is the Medical Clinic


Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Lupron and Docetaxel (75mg/m2) and Testosterone for 7 Days

GnRh (Leuprolide): Leuprolide LUPRON

Docetaxel: 75 mg/m2 given on day 1 of each 3 week cycle

Testosterone Gel: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 7 days

Lupron and Docetaxel (70 mg/m2) and Testosterone for 3 Days

GnRh (Leuprolide): Leuprolide LUPRON

Docetaxel: 70 mg/m2 given on day 1 of each 3 week cycle

Testosterone Gel: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days


Participant Flow:   Overall Study
    Lupron and Docetaxel (75mg/m2) and Testosterone for 7 Days   Lupron and Docetaxel (70 mg/m2) and Testosterone for 3 Days
STARTED   63   39 
COMPLETED   62   38 
NOT COMPLETED   1   1 
Adverse Event                1                0 
Withdrawal by Subject                0                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Lupron and Docetaxel (75mg/m2) and Testosterone for 7 Days

GnRh (Leuprolide): Leuprolide LUPRON

Docetaxel: 75 mg/m2 given on day 1 of each 3 week cycle

Testosterone Gel: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 7 days

Lupron and Docetaxel (70 mg/m2) and Testosterone for 3 Days

GnRh (Leuprolide): Leuprolide LUPRON

Docetaxel: 70 mg/m2 given on day 1 of each 3 week cycle

Testosterone Gel: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days

Total Total of all reporting groups

Baseline Measures
   Lupron and Docetaxel (75mg/m2) and Testosterone for 7 Days   Lupron and Docetaxel (70 mg/m2) and Testosterone for 3 Days   Total 
Overall Participants Analyzed 
[Units: Participants]
 63   39   102 
Age 
[Units: Years]
Median (Standard Deviation)
 65  (25.45584412)   58.5  (26.1629509)   61.5  (30.40559159) 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   43   26   69 
>=65 years   20   13   33 
Gender 
[Units: Participants]
     
Female   0   0   0 
Male   63   39   102 
Region of Enrollment 
[Units: Participants]
     
United States   63   39   102 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   PSA of <_ 0.05 ng/ml After Radical Prostatectomy or Radiation Therapy and PSA <_ 2.0 ng/ml for Patients With Clinical Metastases Without Prior Definitive Therapy   [ Time Frame: Conclusion of the study (at 6 months then at 18 months post-treatment) ]

2.  Secondary:   The Effects of Testosterone Administration on Docetaxel Pharmacokinetics.   [ Time Frame: at Cycle 1 and 2 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Dana Rathkopf
Organization: Memorial Sloan-Kettering Cancer Center
phone: 646-422-4379
e-mail: rathkopd@mskcc.org



Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00587431     History of Changes
Obsolete Identifiers: NCT00070369
Other Study ID Numbers: 03-076
Study First Received: December 21, 2007
Results First Received: January 21, 2014
Last Updated: August 5, 2014